Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low risk of new dysplastic lesions in an inflammatory bowel disease population study with dye chromoendoscopy.
Sicilia B, González-Lama Y, Velayos B, Suárez P, Maroto-Martín C, Nuñez A, Hernández L, Sáiz-Chumillas RM, Relea L, Fernández-Salazar L, Sierra-Ausín M, Barrio Andrés J, Muñoz F, Arias García L. Sicilia B, et al. Among authors: gonzalez lama y. Endosc Int Open. 2023 May 17;11(5):E490-E496. doi: 10.1055/a-2048-2279. eCollection 2023 May. Endosc Int Open. 2023. PMID: 37206695 Free PMC article.
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Pérez-Calle JL, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Carneros JA, López P, Mendoza JL, Milicua JM, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD). González-Lama Y, et al. Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6. doi: 10.1157/13125587. Gastroenterol Hepatol. 2008. PMID: 18783686
Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A, Taxonera C, Casis B, Tabernero S, Bermejo F, Martinez-Silva F, Mendoza JL, Martinez-Montiel P, Carneros JA, Sanchez F, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid. Gonzalez-Lama Y, et al. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1609-14. Hepatogastroenterology. 2008. PMID: 19102352
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.
Fortea-Ormaechea JI, González-Lama Y, Casis B, Chaparro M, López Serrano P, Van Domselaar M, Bermejo F, Pajares R, Ponferrada A, Vera MI, Martínez Montiel P, Gisbert JP, Pérez-Calle JL, López San Román A, Abreu L, Menchén LA, Marín-Jiménez I. Fortea-Ormaechea JI, et al. Gastroenterol Hepatol. 2011 Aug-Sep;34(7):443-8. doi: 10.1016/j.gastrohep.2011.04.001. Epub 2011 Jul 2. Gastroenterol Hepatol. 2011. PMID: 21724297
Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
González-Lama Y, Suárez C, González-Partida I, Calvo M, Matallana V, de la Revilla J, Magaz M, Bernardo C, Agudo B, Ibarrola P, Relea L, Arévalo J, Vera MI, Abreu L. González-Lama Y, et al. J Crohns Colitis. 2016 Jan;10(1):55-60. doi: 10.1093/ecco-jcc/jjv187. Epub 2015 Oct 31. J Crohns Colitis. 2016. PMID: 26520164
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP. Casanova MJ, et al. Am J Gastroenterol. 2017 Jan;112(1):120-131. doi: 10.1038/ajg.2016.569. Epub 2016 Dec 13. Am J Gastroenterol. 2017. PMID: 27958281 Free article.
Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life.
Aladrén BS, González-Lama Y, García-Alvarado M, Sierra M, Barrio JA, Vicente VP, Hernández L, Velayos B, Garcia LA, Relea L, Suarez P, Atienza R, Vásquez M, Fernández-Salazar L, Muñoz F; GEICYL (group of inflammatory bowel disease of Castilla y León). Aladrén BS, et al. Endosc Int Open. 2019 Jun;7(6):E743-E750. doi: 10.1055/a-0839-4514. Epub 2019 May 17. Endosc Int Open. 2019. PMID: 31157291 Free PMC article.
79 results